Actavis, a leading global specialty pharmaceutical company, has launched a generic version of Fougera's Temovate (clobetasol cream 0.05 per cent) in the US markets. The launch strengthens Actavis' growing portfolio of valuable topical products and demonstrates the deep expertise of the company's global R&D and supply chain capabilities.
Temovate is a high-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. For the 12 months ended January 15, 2015, Temovate had total US brand and generic sales of approximately $185 million, according to IMS Health data.